CD276 antibody (Biotin)

Catalog No. ABIN7077083

Product Details anti-CD276 Antibody (Biotin)

Target: CD276

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CD276 antibody is conjugated to Biotin

Application: Flow Cytometry (FACS)

Characteristics: The clone DCN.70, a mouse monoclonal antibody selectively binds with a k type I membrane protein commonly known as CD276, a member of B7-H3 immunoregulatory family. It is not expressed by lymphocytes or granulocytes but weakly expressed on resting monocytes. Increased expression is observed on monocytes derived dendritic cells as well as in a variety of cancer types, including breast, pancreatic, and ovarian cancer. CD276 expression has been correlated with poor survival in ovarian cancer subjects. CD276 blockade, especially when combined with an anti-PD-1 blockade, is a promising strategy for the treatment of B7-H3-expressing NSCLCs that arerefractory to anti-PD-1 therapy, making CD276 a promising clinical molecular target.

Purification: Purified

Purity: >95 %

Grade: GMP Grade

Immunogen: Human Dendritic Cells

Clone: DCN-70

Isotype: IgG1 kappa

Application Details

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: PBS pH 7.2, 0.09 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Target Details for CD276

Target: CD276

Alternative Name: CD276 (CD276 Products)

Synonyms: sc:d0645 antibody, zgc:158279 antibody, 6030411F23Rik antibody, AU016588 antibody, B7RP-2 antibody, B7h3 antibody, B7H3 antibody, 4Ig-B7-H3 antibody, B7-H3 antibody, CD276 molecule antibody, CD276 molecule S homeolog antibody, CD276 antigen antibody, Cd276 molecule antibody, CD276 antibody, cd276.S antibody, cd276 antibody, Cd276 antibody

Background: The clone DCN.70, a mouse monoclonal antibody selectively binds with a k type I membrane protein commonly known as CD276, a member of B7-H3 immunoregulatory family. It is not expressed by lymphocytes or granulocytes but weakly expressed on resting monocytes. Increased expression is observed on monocytes derived dendritic cells as well as in a variety of cancer types, including breast, pancreatic, and ovarian cancer. CD276 expression has been correlated with poor survival in ovarian cancer subjects. CD276 blockade, especially when combined with an anti-PD-1 blockade, is a promising strategy for the treatment of B7-H3-expressing NSCLCs that arerefractory to anti-PD-1 therapy, making CD276 a promising clinical molecular target.

Gene ID: 80381

UniProt: Q5ZPR3

Pathways: Cancer Immune Checkpoints